Jennifer S Guimbellot

List of Publications by Year
in descending order

Version: 2024-02-01

23 papers	614 citations	567281 15 h-index	713466 21 g-index
23 all docs	23 docs citations	23 times ranked	843 citing authors

#	Article	IF	Citations
1	Efficient Intracellular Processing of the Endogenous Cystic Fibrosis Transmembrane Conductance Regulator in Epithelial Cell Lines. Journal of Biological Chemistry, 2004, 279, 22578-22584.	3.4	118
2	Correlation of microRNA levels during hypoxia with predicted target mRNAs through genome-wide microarray analysis. BMC Medical Genomics, 2009, 2, 15.	1.5	65
3	Role of Oxygen Availability in CFTR Expression and Function. American Journal of Respiratory Cell and Molecular Biology, 2008, 39, 514-521.	2.9	47
4	Human Nasal Epithelial Organoids for Therapeutic Development in Cystic Fibrosis. Genes, 2020, 11, 603.	2.4	40
5	Nasospheroids permit measurements of CFTR-dependent fluid transport. JCI Insight, 2017, 2, .	5.0	40
6	Long term clinical effectiveness of ivacaftor in people with the G551D CFTR mutation. Journal of Cystic Fibrosis, 2021, 20, 213-219.	0.7	33
7	EWS/FLI function varies in different cellular backgrounds. Experimental Cell Research, 2003, 290, 414-419.	2.6	32
8	Toward inclusive therapy with CFTR modulators: Progress and challenges. Pediatric Pulmonology, 2017, 52, S4-S14.	2.0	32
9	Tracheostomy in children: Epidemiology and clinical outcomes. Pediatric Pulmonology, 2018, 53, 1269-1275.	2.0	32
10	Effectiveness of ivacaftor in cystic fibrosis patients with non-G551D gating mutations. Journal of Cystic Fibrosis, 2019, 18, 102-109.	0.7	30
11	Females with Cystic Fibrosis Demonstrate a Differential Response Profile to Ivacaftor Compared with Males. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 996-998.	5.6	26
12	Use of elexacaftor/tezacaftor/ivacaftor among cystic fibrosis lung transplant recipients. Journal of Cystic Fibrosis, 2022, 21, 745-752.	0.7	23
13	Sensitivity of ivacaftor to drugâ€drug interactions with rifampin, a cytochrome P450 3A4 inducer. Pediatric Pulmonology, 2018, 53, E6-E8.	2.0	19
14	CFTR function and clinical response to modulators parallel nasal epithelial organoid swelling. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2021, 321, L119-L129.	2.9	19
15	Co-cultured microfluidic model of the airway optimized for microscopy and micro-optical coherence tomography imaging. Biomedical Optics Express, 2019, 10, 5414.	2.9	18
16	Variable cellular ivacaftor concentrations in people with cystic fibrosis on modulator therapy. Journal of Cystic Fibrosis, 2020, 19, 742-745.	0.7	16
17	Ivacaftor-elexacaftor-tezacaftor and tacrolimus combination in cystic fibrosis. Journal of Cystic Fibrosis, 2022, 21, e8-e10.	0.7	10
18	Potential pathogenicity of Inquilinus limosus in a pediatric patient with cystic fibrosis. Pediatric Pulmonology, 2018, 53, E21-E23.	2.0	6

#	Article	IF	Citations
19	Combination CFTR modulator therapy in children and adults with cystic fibrosis. Lancet Respiratory Medicine,the, 2021, 9, 677-679.	10.7	4
20	Highlights from the 2019 North American Cystic Fibrosis Conference. Pediatric Pulmonology, 2020, 55, 2225-2232.	2.0	2
21	Culture and Imaging of Human Nasal Epithelial Organoids. Journal of Visualized Experiments, 2021, , .	0.3	2
22	1263. Critical Care Medicine, 2013, 41, A324-A325.	0.9	0
23	Targeting the Underlying Defect in CFTR with Small Molecule Compounds. Respiratory Medicine, 2020, , 483-501.	0.1	0